JNJ-64041757

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for JNJ-64041757, covering 2019-12-11 to 2025-02-03. Get the full timeline:

Most recent: Clinical Trial Update: Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer [Phase 1]

See pricing